Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026? | The Motley Fool

In the healthcare investment landscape for 2026, Johnson & Johnson (JNJ) offers stability with a diversified portfolio and strong operational efficiency, reporting $94 billion in revenue and a net income of $27 billion. Conversely, Eli Lilly (LLY) showcases rapid growth, achieving $65.2 billion in revenue, driven by blockbuster...